The first quarter of 2025 brought significant advances in gastroenterology, including FDA approvals for mirikizumab and guselkumab, expanding treatment options for Crohn’s disease. Apraglutide’s rolling NDA submission also raised hope for patients with short bowel syndrome. Promising clinical trial data emerged for fecal microbiota transplantation in type 1 diabetes-related gastroenteropathy and icotrokinra for ulcerative colitis. In colorectal cancer screening, annual FIT testing was validated as the most effective and cost-efficient method for low-adherence populations.
Keep Reading
Add A Comment